Found: 10
Select item for more details and to access through your institution.
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1795, doi. 10.1177/13524585231205708
- By:
- Publication type:
- Article
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 13, p. 1725, doi. 10.1177/1352458517729464
- By:
- Publication type:
- Article
Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 6, p. 795, doi. 10.1177/1352458517707345
- By:
- Publication type:
- Article
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
- Published in:
- Journal of Neurology, 2020, v. 267, n. 10, p. 2851, doi. 10.1007/s00415-020-09835-y
- By:
- Publication type:
- Article
Rapunzel Syndrome Associated With Triple Simultaneous Trichobezoar: A Case Report.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420987941
- By:
- Publication type:
- Article
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420987941
- By:
- Publication type:
- Article
Current and emerging therapies in multiple sclerosis: a systematic review.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2012, v. 5, n. 4, p. 205, doi. 10.1177/1756285612450936
- By:
- Publication type:
- Article
Symptomatic therapy in multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 2, p. 83, doi. 10.1177/1756285611400658
- By:
- Publication type:
- Article